These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37026950)

  • 1. Ischaemic colitis during pegylated interferon-alpha monotherapy for chronic hepatitis B: A case report.
    Liu Y; Chen H; Xu ZY
    Medicine (Baltimore); 2023 Apr; 102(14):e33378. PubMed ID: 37026950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ischemic colitis during interferon-ribavirin therapy for chronic hepatitis C: a case report.
    Baik SJ; Kim TH; Yoo K; Moon IH; Cho MS
    World J Gastroenterol; 2012 Aug; 18(31):4233-6. PubMed ID: 22919260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.
    Leung Y; Urbanski SJ; Schindel L; Myers RP
    Can J Gastroenterol; 2006 Oct; 20(10):661-3. PubMed ID: 17066158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.
    Hu Y; Ye YZ; Ye LJ; Wang XH; Yu H
    World J Pediatr; 2019 Dec; 15(6):595-600. PubMed ID: 31487005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; di Paolo D; Demelia L; Sorbello O; Nosotti L; Angelico M
    Antivir Ther; 2013; 18(1):57-64. PubMed ID: 22872648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
    Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with pegylated interferon alpha-2b and adefovir dipivoxil in HBeAg-positive chronic hepatitis B versus interferon alone: a prospective, randomized study.
    Liu YH; Wu T; Sun N; Wang GL; Yuan JZ; Dai YR; Zhou XH
    J Huazhong Univ Sci Technolog Med Sci; 2014 Aug; 34(4):542-547. PubMed ID: 25135724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B.
    Boglione L; Cariti G; Di Perri G; D'Avolio A
    J Med Virol; 2016 Nov; 88(11):1953-9. PubMed ID: 27017932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa.
    Yeh ML; Huang JF; Yu ML; Chuang WL
    Expert Rev Gastroenterol Hepatol; 2021 Apr; 15(4):427-435. PubMed ID: 33338385
    [No Abstract]   [Full Text] [Related]  

  • 12. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
    de Niet A; Jansen L; Stelma F; Willemse SB; Kuiken SD; Weijer S; van Nieuwkerk CMJ; Zaaijer HL; Molenkamp R; Takkenberg RB; Koot M; Verheij J; Beuers U; Reesink HW
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):576-584. PubMed ID: 28522204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
    Luo X; Yu JX; Xie L; Ma WJ; Wang LH
    Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience.
    Ratnam D; Dev A; Nguyen T; Sundararajan V; Harley H; Cheng W; Lee A; Rusli F; Chen R; Bell S; Pianko S; Sievert W
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1447-53. PubMed ID: 22168789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C.
    Choi JW; Lee JS; Paik WH; Song TJ; Kim JW; Bae WK; Kim KA; Kim JG
    Clin Mol Hepatol; 2016 Mar; 22(1):168-71. PubMed ID: 27044768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
    Dogan UB; Golge N; Akin MS
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bilateral non-arteritic ischemic optic neuropathy during treatment of viral hepatitis C with pegylated interferon and Ribavirin].
    Iferkhass S; Elasri F; Chatioui S; Khoyaali A; Bargach T; Reda K; Oubaaz A
    J Fr Ophtalmol; 2015 Jan; 38(1):34-40. PubMed ID: 25533994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ischemic colitis during interferon-alpha treatment for chronic active hepatitis C.
    Tada H; Saitoh S; Nakagawa Y; Hirana H; Morimoto M; Shima T; Shimamoto K; Okanoue T; Kashima K
    J Gastroenterol; 1996 Aug; 31(4):582-4. PubMed ID: 8844482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.
    Chan HL; Leung NW; Hui AY; Wong VW; Liew CT; Chim AM; Chan FK; Hung LC; Lee YT; Tam JS; Lam CW; Sung JJ
    Ann Intern Med; 2005 Feb; 142(4):240-50. PubMed ID: 15710957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.